Japanese Antibacterial Drug Management for Cardiac Sarcoidosis (J‐ACNES): A multicenter, open‐label, randomized, controlled study

• DOI: 10.1002/joa3.12084
• Publication Date: 2018-08-31T12:18:05Z
• Authors: Kohei Ishibashi; Yoshinobu Eishi; Nobuhiro Tahara; Masanori Asakura; Naka Sakamoto; Kazufumi Nakamura; Yoichi Takaya; Tomohisa Nakamura; Yoshikazu Yazaki; Tetsuo Yamaguchi; Koko Asakura; Toshihisa Anzai; Teruo Noguchi; Satoshi Yasuda; Fumio Terasaki; Toshimitsu Hamasaki; Kengo Kusano
• Keywords: 0301 basic medicine; 03 medical and health sciences; RC666-701; corticosteroid therapy; Diseases of the circulatory (Cardiovascular) system; Propionibacterium acnes; Original Articles; antibacterial drug; cardiac sarcoidosis; 3. Good health

AbstractBackgroundCardiac sarcoidosis (CS) is a noncaseating granulomatous disease of unknown etiology. Lifelong immunosuppressive therapy, most frequently using corticosteroids, is a standard therapy to control hypersensitivity of immune reactions and prevent inflammation. However, it sometimes causes various systemic adverse effects and requires dose escalation. Thus, additional therapy may be required for the treatment of this disease. Recently, Propionibacterium acnes (P. acnes) was reported as one of the etiologic agents of CS, indicating that antibacterial drugs (ABD) may be effective for the treatment of CS. The objective of this study was to investigate the effect of ABD treatment, in addition to standard corticosteroid therapy, in patients with CS.MethodsThe Japanese Antibacterial Drug Management for Cardiac Sarcoidosis (J‐ACNES) trial was designed as a prospective, multicenter, randomized, open‐label, controlled clinical trial. The patients will be randomized to receive either standard corticosteroid therapy plus ABD therapy (ABD group) or standard corticosteroid therapy (standard group). The primary endpoint is change in the total standardized uptake value at 6 months vs baseline using fluorine‐18 fluorodeoxyglucose positron emission tomography and computed tomography. Secondary endpoints include efficacy, prognosis, and safety.ResultsThe results of this study are currently under investigation.ConclusionThe J‐ACNES trial will be the first prospective study assessing the clinical benefit and safety of ABD therapy, in addition to corticosteroid treatment, in patients with CS. Our findings may improve treatment of patients with CS, as additional ABD therapy reduces recurrence of inflammation and elucidates the mechanism of sarcoidosis.